Athenex Inc

Athenex — Corporate Update (September 2020)

28 slides from Athenex's corporate update, Sep 8, 2020

  1. Slide 1: Conference Call & Webcast: Oral Paclitaxel and Encequidar

    Exhibit 99.2 CONFERENCE CALL & WEBCAST: ORAL PACLITAXEL AND ENCEQUIDAR September 8, 2020 NASDAQ:ATNX www.athenex.comExhibit 99.2 CONFERENCE CALL & WEBCAST: ORAL PACLITAXEL AND ENCEQUIDAR September 8, 2020 NASDAQ:ATNX www.athenex.com

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this presentation constitute forward- looking statements. These statements include descriptions regarding the intent, belief or current expectations of Athenex, Inc. (the “

  3. Slide 3: Agenda and Introduction

    Agenda and Introduction INTRODUCTION Johnson Lau, Chief Executive Officer ORAL PACLITAXEL: DEVELOPMENT UPDATE • NDA Filing for Metastatic Breast Cancer • Initiation of Oral Paclitaxel in the I-SPY 2 Trial Rudolf Kwan, Chief Medical Officer ORAL PACLITAXEL: COMMERCIAL STRATEGY Timothy Cook, SVP, Glob

  4. Slide 4: Increasing Importance of Oral Chemotherapy Options

    Increasing Importance of Oral Chemotherapy Options • Consideration of alternative dosing schedule to allow for fewer in-person visits to the cancer center and/or the infusion center • Switch from infusional therapy to oral oncolytics if equivalent formulation is available 4 Source: https://www.nccn.

  5. Slide 5: Development Update: Oral Paclitaxel NDA for Metastatic Breast Cancer

    D E V E L O P M E N T U P D A T E : O r a l P a c l i t a x e l N D A f o r M e t a s t a t i c B r e a s t C a n c e rD E V E L O P M E N T U P D A T E : O r a l P a c l i t a x e l N D A f o r M e t a s t a t i c B r e a s t C a n c e r

  6. Slide 6: Oral Paclitaxel and Encequidar Regulatory Update

    Oral Paclitaxel and Encequidar Regulatory Update • NDA of Oral Paclitaxel for metastatic breast cancer accepted for filing by the U.S. FDA • Priority Review granted • U.S. FDA grants Priority Review to applications for potential therapies that, if approved, would be significant improvements in the s

  7. Slide 7: Study Met Primary ORR Endpoint

    Study Met Primary ORR Endpoint Statistically Significant Improvement in ORR Compared to IV Paclitaxel (Presented at 2019 SABCS) Confirmed Response Rate Confirmed Response Rate (ITT Population) (Prespecified mITT Population) Δ=14.8% Δ=12.4% p=0.005 p=0.011 40.4% 35.8% 25.6% 23.4% Oral Paclitaxel Grou

  8. Slide 8: Overall Survival in Prespecified mITT Population Demonstrated Survival Benefit

    Overall Survival in Prespecified mITT Population Demonstrated Survival Benefit (Data cut: July 2019) (Presented at 2019 SABCS) OPE IVP HR=0.684 (95% CI: 0.475, 0.985) P=0.0353 Months (Relative to Randomization) Numbers of Subjects at Risk 235 229 218 190 162 130 107 84 66 48 42 31 27 23 18 10 7 4 2

  9. Slide 9: Neuropathy-relevant TEAEs (CTCAE Grade ≥2)

    1 Neuropathy-relevant TEAEs (CTCAE Grade ≥2) Safety Population (N=399) (Presented at 2019 SABCS) Numbers of Subjects at Risk OPE 264 263 248 239 225 215 198 185 180 171 158 149 137 128 121 114 103 95 85 78 71 65 60 57 51 IVP 135 129 126 120 117 111 103 96 92 86 70 67 58 52 49 40 34 33 33 29 24 20 20

  10. Slide 10: Development Update: Initiation of Oral Paclitaxel in the I-SPY 2 Trial

    D E V E L O P M E N T U P D A T E : I n i t i a t i o n o f O r a l P a c l i t a x e l i n t h e I - S P Y 2 T r i a lD E V E L O P M E N T U P D A T E : I n i t i a t i o n o f O r a l P a c l i t a x e l i n t h e I - S P Y 2 T r i a l

  11. Slide 11: I-SPY 2 Trial Overview

    I-SPY 2 Trial Overview • I-SPY 2 employs an innovative adaptive randomization trial model, including: Neoadjuvant model Endpoint is pCR Curable population Systemic therapy first I-SPY 2’s early A breast cancer lets you see how surrogate efficacy population where tumors respond to endpoint, pCR, gets

  12. Slide 12: I-SPY 2 Trial: Adaptive Overall Study Schema

    I-SPY 2 Trial: Adaptive Overall Study Schema 12 Source: Quantum Leap Healthcare Collaborative September 2020I-SPY 2 Trial: Adaptive Overall Study Schema 12 Source: Quantum Leap Healthcare Collaborative September 2020

  13. Slide 13: I-SPY 2 Principal Investigators from Leading Cancer Centers

    I-SPY 2 Principal Investigators from Leading Cancer Centers Institution Site PI Name and Title Institution Site PI Name and Title 13 Source: Quantum Leap Healthcare Collaborative September 2020I-SPY 2 Principal Investigators from Leading Cancer Centers Institution Site PI Name and Title Institution

  14. Slide 14: I-SPY 2 Launches New Study Arm with Oral Paclitaxel and Dostarlimab

    Surgery I-SPY 2 Launches New Study Arm with Oral Paclitaxel In Combination with GSK’s dostarlimab (PD-1 Antibody) Goal of Study: Evaluate the safety and efficacy of Oral Paclitaxel in combination with dostarlimab +/- carboplatin in the neoadjuvant breast cancer setting Primary Objective: Determine w

  15. Slide 15: Ongoing Phase II Study of Oral Paclitaxel in Angiosarcoma

    Ongoing Phase II Study of Oral Paclitaxel in Angiosarcoma Interim Data Presented at ASCO20 Virtual Scientific Program 1 Early Onset of Response – CR at Week 13 Baseline Week 1 Week 2 2 Early Onset of Response – CR at Week 6 15 ASCO20 Poster Presentation ”A Phase II Study of Oral Paclitaxel with Ence

  16. Slide 16: I-SPY 2 Agent Timeline

    I-SPY 2 Agent Timeline 16 Source: Quantum Leap Healthcare Collaborative September 2020I-SPY 2 Agent Timeline 16 Source: Quantum Leap Healthcare Collaborative September 2020

  17. Slide 17: Commercial Strategy

    C O M M E R C I A L S T R A T E G YC O M M E R C I A L S T R A T E G Y

  18. Slide 18: Establishing Athenex's Leadership in Oncology

    Establishing Athenex’s Leadership in Oncology Positioning Oral Paclitaxel to become the preferred chemotherapy in metastatic breast cancer (MBC)* • Strong Phase III clinical data, comparing to IV Paclitaxel, in MBC Oral Paclitaxel potential label expansion opportunities to multiple indications* • IV

  19. Slide 19: Commercial Strategy for Oral Paclitaxel in MBC

    Commercial Strategy for Oral Paclitaxel in MBC* Executing a Potential U.S. Launch around Critical Success Factors Emphasize strong clinical data Optimize messaging Increased demand for oral therapies Build company and product awareness Build awareness Highlight strong clinical results Enhance U.S. d

  20. Slide 20: Commercial Preparations on Track

    Commercial Preparations on Track MARKETING SALES MEDICAL AFFAIRS MARKET ACCESS Scientific Trade and distribution “Facing MBC Together” Account targeting communication platform strategy defined campaign launched complete established Data infrastructure being Payer value proposition Brand positioning

  21. Slide 21: Market Opportunity for Oral Paclitaxel in MBC in the U.S.

    Market Opportunity for Oral Paclitaxel in MBC in the U.S. Metastatic Breast Cancer HER2+ HR+/HER2- TNBC Unknown 1 1 1 1 ~14% ~68% ~10% ~8% Endocrine therapy Oral Paclitaxel and Common regimens 1L +/- CDK 4 & 6 inhibitor Encequidar • Herceptin in combination with paclitaxel • Herceptin Oral Paclitaxe

  22. Slide 22: Label Expansion Strategies

    L A B E L E X P A N S I O N S T R A T E G I E SL A B E L E X P A N S I O N S T R A T E G I E S

  23. Slide 23: Label Expansion Strategies

    Label Expansion Strategies Pursue opportunities Pursue emerging where paclitaxel is, and combination opportunities will continue to be, the standard of care Time to Regulatory Commercial approval pathway opportunity - Probability of Unmet success medical need Financial Competitive Partner investment

  24. Slide 24: Potential Areas of Interest

    Potential Areas of Interest Pursue opportunities Pursue emerging where paclitaxel is, and combination opportunities will continue to be, the standard of care Expanding into indications where Combining with immunotherapies Paclitaxel is SOC Early stage breast cancer Lung cancer Ovarian cancer Gastroe

  25. Slide 25: Opportunity to Expand Oral Paclitaxel's Addressable Market

    Opportunity to Expand Oral Paclitaxel’s Addressable Market Potential Addressable US Patients: 545,000 > 545,000 (US Incidence) 25,000 42,000 18,000 35,000 149,000 276,000 Early Stage BC Metastatic 70,000 Current Total Breast Metastatic Metastatic Metastatic Metastatic Head Metastatic 1 Addressable C

  26. Slide 26: Key Takeaways

    K E Y T A K E A W A Y SK E Y T A K E A W A Y S

  27. Slide 27: Oral Paclitaxel is the First Step in Establishing Leadership in Oral Chemotherapy

    Oral Paclitaxel is the first step in establishing Athenex’s leadership in oral chemotherapy and oncology Advance development of the broader Orascovery pipeline Oral Paclitaxel provides further validation of the technology platform Expand usage of Oral Paclitaxel in other cancer Establish Oral Oral d

  28. Slide 28: Q&A Thank You

    Q&A THANK YOU Our goal is to become a global leader in bringing innovative cancer treatments to the market and improving health outcomes NASDAQ:ATNX www.athenex.comQ&A THANK YOU Our goal is to become a global leader in bringing innovative cancer treatments to the market and improving health outcomes

Athenex — Corporate Update (September 2020) on 6ix